The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial
NCT03412591
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Sleep Disturbance
Craving
Cortisol; Hypersecretion
Interventions
DRUG:
Suvorexant 20 mg
Sponsor
Milton S. Hershey Medical Center